Uhl, who shepherded OGD into the user fee era, will retire in February.
Kathleen "Cook" Uhl, who has lead US FDA's Office of Generic Drugs as it was beginning its user fee program and through its first reauthorization, plans to retire in early 2019.
Center for Drug Evaluation and Research Director Janet Woodcock announced Uhl's departure July 17 in a memo to staff. Uhl...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
